Effect of Vitamin D and turmeric in lymphoma patients.
Not Applicable
- Conditions
- Health Condition 1: C833- Diffuse large B-cell lymphoma
- Registration Number
- CTRI/2020/06/025818
- Lead Sponsor
- JIPMER Intramural fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Newly diagnosed patients of diffuse large B cell lymphoma (DLBCL) [based on the 2008 World Health Organization classification] to be started on R-CHOP with serum 25 hydroxy D level less than
30 ng/ml.
Exclusion Criteria
Subjects previously treated with chemotherapy except for prefix chemotherapy, radiotherapy, immunotherapy or experimental therapies for lymphoma or other malignancy.
History of other cancer within the past 5 years except curatively treated non- melanoma skin cancer or in situ carcinoma of
uterine cervix.
Subjects diagnosed with double hit or triple
hit lymphoma.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Event Free Survival at the end of two years (EFS24) of diagnosis in patients with DLBCLTimepoint: Two years
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) at the end of three years of diagnosis in patients with DLBCLTimepoint: Three years